中华肿瘤杂志
中華腫瘤雜誌
중화종류잡지
CHINESE JOURNAL OF ONCOLOGY
2012年
7期
501-505
,共5页
陈雅敏%吴旭兰%张力维%许昕%刘基巍
陳雅敏%吳旭蘭%張力維%許昕%劉基巍
진아민%오욱란%장력유%허흔%류기외
结直肠肿瘤%XPD751基因%DNA修复%多态性,单核苷酸%治疗结果
結直腸腫瘤%XPD751基因%DNA脩複%多態性,單覈苷痠%治療結果
결직장종류%XPD751기인%DNA수복%다태성,단핵감산%치료결과
Colorectal neoplasms%XPD751%DNA repair%Polymorphism,singlenucleotide%Treatment outcome
目的 探讨结直肠癌患者DNA修复基因XPD751单核苷酸多态性与铂类药物化疗疗效的关系.方法 经病理学确诊的晚期结直肠癌患者98例,均行奥沙利铂联合氟尿嘧啶化疗方案(FOLFOX)治疗.所有患者化疗前抽取静脉血,成功提取DNA,采用多聚酶链反应-限制性片段长度多态性分析技术检测XPD751单核苷酸多态性.比较不同基因型与预后的关系.结果 98例结直肠癌患者中,DNA修复基因XPD751各基因型频度分别为Lys/Lys基因型占77.6％( 76/98),Lys/Gln基因型占17.4％( 17/98),Gln/Gln基因型占5.1％(5/98).98例结直肠癌患者部分缓解44例(44.9％),疾病稳定34例(34.7％),疾病进展20例(20.4％).携带XPD751 Lys/Lys基因型的患者化疗的有效率为50.0％,Lys/Gln基因型为29.4％,Gln/Gln基因型为20.0％.携带Lys/Lys基因型患者的化疗疗效优于携带Lys/Gln基因型的患者,差异有统计学意义(P＜0.05).Logistic回归分析显示,携带Lys/Lys基因型的患者接受FOLFOX方案化疗的敏感性是携带Lys/Gln基因型患者的3.800倍(OR=3.800,P=0.016).98例结直肠癌患者的疾病进展时间(TTP)为10.1个月,携带XPD751 Lys/Lys基因型患者的中位TTP为11.3个月,携带Lys/Gln和Gln/Gln基因型患者的中位TTP为2.9个月.携带Lys/Lys与至少有1个G1n基因型患者的中位TTP比较,差异有统计学意义(P＜0.05).Cox回归分析显示,携带Lys/Gln基因型的患者疾病进展的风险是携带Lys/Lys基因型患者的2.035倍(RR=2.035,P=0.001).结论 DNA修复基因XPD751单核苷酸多态性可能与结直肠癌患者对FOLFOX方案化疗敏感性有关,检测XPD751单核苷酸多态性可能成为预测接受FOLFOX方案化疗后结直肠癌患者预后的指标.
目的 探討結直腸癌患者DNA脩複基因XPD751單覈苷痠多態性與鉑類藥物化療療效的關繫.方法 經病理學確診的晚期結直腸癌患者98例,均行奧沙利鉑聯閤氟尿嘧啶化療方案(FOLFOX)治療.所有患者化療前抽取靜脈血,成功提取DNA,採用多聚酶鏈反應-限製性片段長度多態性分析技術檢測XPD751單覈苷痠多態性.比較不同基因型與預後的關繫.結果 98例結直腸癌患者中,DNA脩複基因XPD751各基因型頻度分彆為Lys/Lys基因型佔77.6％( 76/98),Lys/Gln基因型佔17.4％( 17/98),Gln/Gln基因型佔5.1％(5/98).98例結直腸癌患者部分緩解44例(44.9％),疾病穩定34例(34.7％),疾病進展20例(20.4％).攜帶XPD751 Lys/Lys基因型的患者化療的有效率為50.0％,Lys/Gln基因型為29.4％,Gln/Gln基因型為20.0％.攜帶Lys/Lys基因型患者的化療療效優于攜帶Lys/Gln基因型的患者,差異有統計學意義(P＜0.05).Logistic迴歸分析顯示,攜帶Lys/Lys基因型的患者接受FOLFOX方案化療的敏感性是攜帶Lys/Gln基因型患者的3.800倍(OR=3.800,P=0.016).98例結直腸癌患者的疾病進展時間(TTP)為10.1箇月,攜帶XPD751 Lys/Lys基因型患者的中位TTP為11.3箇月,攜帶Lys/Gln和Gln/Gln基因型患者的中位TTP為2.9箇月.攜帶Lys/Lys與至少有1箇G1n基因型患者的中位TTP比較,差異有統計學意義(P＜0.05).Cox迴歸分析顯示,攜帶Lys/Gln基因型的患者疾病進展的風險是攜帶Lys/Lys基因型患者的2.035倍(RR=2.035,P=0.001).結論 DNA脩複基因XPD751單覈苷痠多態性可能與結直腸癌患者對FOLFOX方案化療敏感性有關,檢測XPD751單覈苷痠多態性可能成為預測接受FOLFOX方案化療後結直腸癌患者預後的指標.
목적 탐토결직장암환자DNA수복기인XPD751단핵감산다태성여박류약물화료료효적관계.방법 경병이학학진적만기결직장암환자98례,균행오사리박연합불뇨밀정화료방안(FOLFOX)치료.소유환자화료전추취정맥혈,성공제취DNA,채용다취매련반응-한제성편단장도다태성분석기술검측XPD751단핵감산다태성.비교불동기인형여예후적관계.결과 98례결직장암환자중,DNA수복기인XPD751각기인형빈도분별위Lys/Lys기인형점77.6％( 76/98),Lys/Gln기인형점17.4％( 17/98),Gln/Gln기인형점5.1％(5/98).98례결직장암환자부분완해44례(44.9％),질병은정34례(34.7％),질병진전20례(20.4％).휴대XPD751 Lys/Lys기인형적환자화료적유효솔위50.0％,Lys/Gln기인형위29.4％,Gln/Gln기인형위20.0％.휴대Lys/Lys기인형환자적화료료효우우휴대Lys/Gln기인형적환자,차이유통계학의의(P＜0.05).Logistic회귀분석현시,휴대Lys/Lys기인형적환자접수FOLFOX방안화료적민감성시휴대Lys/Gln기인형환자적3.800배(OR=3.800,P=0.016).98례결직장암환자적질병진전시간(TTP)위10.1개월,휴대XPD751 Lys/Lys기인형환자적중위TTP위11.3개월,휴대Lys/Gln화Gln/Gln기인형환자적중위TTP위2.9개월.휴대Lys/Lys여지소유1개G1n기인형환자적중위TTP비교,차이유통계학의의(P＜0.05).Cox회귀분석현시,휴대Lys/Gln기인형적환자질병진전적풍험시휴대Lys/Lys기인형환자적2.035배(RR=2.035,P=0.001).결론 DNA수복기인XPD751단핵감산다태성가능여결직장암환자대FOLFOX방안화료민감성유관,검측XPD751단핵감산다태성가능성위예측접수FOLFOX방안화료후결직장암환자예후적지표.
Objective To investigate whether single nucleotide polymorphism (SNP) in DNA repair gene XPD751 is associated with sensitivity and time to progression (TTP) for platinum-containing combination chemotherapy in advanced colorectal carcinoma.Methods A total of 98 patients pathologically diagnosed as advanced colorectal cancer were treated with FOLFOX chemotherapy.TheDNA of peripheral blood-leukocytes was obtained before treatment,and XPD genetype was detected by PCR-RFLP analysis.Results The frequency of XPD751 Lys/lys was 76 cases (77.6％),lys/Gln 17 cases ( 17.4％ ),and Gln/Gln genetype 5 cases (5.1％ ).The effective rate of FOLFOX chemotherapy among patients with XPD751 Lys/lys was 50.0％,lys/Gln 29.4％,and Gln/Gln genetypes 20.0％.The difference between Lys/lys and lys/Gln was statistically significant,X2 =4.04,P ＜ 0.05.The results indicated that the failure of chemotherapy in patients with Lys/Lys genetype was 3.8-fold to those with Lys/Gln,by adjusting of gender,age,and tumor metastasis (OR =3.800).The MTTP of the 98 patients was 10.1 months.The MTTP was 11.3 months for patients with lys/Lys genotypes of XPD751 gene and 2.9 months for patients with Lys/Gln and Gln/Gln genotypes of XPD751 gene,the difference between Lys/Lys and at least one Gln was significant (P ＜ 0.05 ).Conclusions Single nueleotide polymorphism of XPD751 correlates with the clinical response to FOLFOX chemotherapy.XPD751 genetic polymorphisms may be associated with TTP of advanced colorectal carcinoma patients treated with oxaliplatin as the first line chemotherapy. XPD751 genotype detected by the PCR-RFLP method may be a predictor of prognosis for FOLFOX chemotherapy.
